CAMBRIDGE, Mass., June 19 /PRNewswire/ -- Cytel's renowned experts will present the results of their latest research on the design and implementation of innovative adaptive clinical trials at the 42nd Annual Meeting of the Drug Information Association (DIA), June 18 to June 22, 2006, in Philadelphia.
Adaptive trial designs allow the use of information gained from an ongoing trial to refine the study, thereby improving clinical trial success rates, as well as identifying unsuccessful trials earlier. Conventional trials cannot be modified once begun, significantly contributing to costly development inefficiencies and the alarmingly high rate of trial failures.
Adaptive clinical trials hold the promise of radically altering the clinical process, and boosting the biopharmaceutical industry's return on investment in drug and device development.
Speaking at the DIA meeting are Dr. Cyrus Mehta, Founder and President, Cytel Inc., Dr. Nitin Patel, Founder, Chairman, and Chief Technology Officer, and Dr. Jerald Schindler, President of Cytel's Pharmaceutical Research Division.
Dr. Mehta will present the talk: "Exact Confidence Intervals Following an Adaptive Design". Dr. Patel will present "Modeling and Forecasting Patient Recruitment".
Dr. Schindler, a DIA session organizer, will participate in:
"Tools to Ease the Transition to the Use of Adaptive Clinical Trials"
"Interoperability: What It Means for Clinical Researchers, Statisticians, and IT"
"Strategies for the Use of Adaptive Designs to Increase the Success of the Drug Portfolio"
Session times are available at: www.cytel.com/News/conferences.asp
About Cytel
Cytel Inc. is a leading provider of clinical trial consulting services and specialized statistical software for the bio-pharmaceutical, medical device, academic, and government research markets. Cytel's unique expertise in adaptive, flexible designs enables trial sponsors to improve drug development process efficiencies and trial success rates. Cytel's East(R) system is widely used by biostatisticians and clinicians in industry, academia, and the FDA to design, monitor and simulate group sequential, and adaptive clinical trials.
Cytel Inc.CONTACT: Michael Weitz of Cytel Inc., +1-617-528-7132, mike@cytel.com
